AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE
AgNovos Bioscience announces that more than 150 patients have been enrolled in the RESTORE randomized, controlled trial of AGN1 LOEP.
Keep up to date on AgNovos events and related news
AgNovos is pleased to announce that Mr. Adam Lowe has joined the Company as Vice President of Operations and Quality.
AgNovos is pleased to announce that Paul Higham, PhD has joined the Company as Chief Scientific Officer.